Literature DB >> 33030104

Advancing toward normal operations for arenas and stadiums.

Justine Parker1, Corey Boles2, Olivia Leleck3, Amanda Buerger2, Natalie Egnot3, Alexander Sundermann3, Elizabeth Bussmann4.   

Abstract

The reopening of arenas and stadiums following closures due to the 2019 coronavirus disease (COVID-19) pandemic presents unique challenges related to large crowds and close contact between players, vendors, and spectators. While each venue should be assessed individually for development and implementation of reopening plans, the general guidance presented in this document can serve as a minimum baseline for considerations to reduce the risk of COVID-19 transmission in these venues. The intention of these guidelines is to provide a layered approach to risk mitigation for various aspects of particular concern in arenas and stadiums, including crowd management, tailgating and parking, restrooms, high-contact surfaces, face masks, food and merchandising, communications, athletes and support staff, press and third parties, intermissions/breaks, and downtime. The implementation of these multifaceted approaches in each area of concern, along with the integration of regulations and requirements from local, state, and federal government bodies and agencies, will reduce the risk of a single point of failure and offer some protection to those at arenas and stadiums from COVID-19 transmission. The approaches outlined are dynamic and should be regularly reviewed and revised as new information becomes available regarding the transmission of COVID-19.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; arenas; sports; stadiums

Mesh:

Year:  2020        PMID: 33030104     DOI: 10.1177/0748233720964651

Source DB:  PubMed          Journal:  Toxicol Ind Health        ISSN: 0748-2337            Impact factor:   2.273


  1 in total

1.  Modelling the dynamic relationship between spread of infection and observed crowd movement patterns at large scale events.

Authors:  Philip Rutten; Michael H Lees; Sander Klous; Hans Heesterbeek; Peter M A Sloot
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.